2021
The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells
Mashayekhi M, Wanjalla CN, Warren CM, Simmons JD, Ghoshal K, Pilkinton M, Bailin SS, Gabriel CL, Pozzi A, Koethe JR, Brown NJ, Kalams SA, Luther JM. The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins And Other Lipid Mediators 2021, 158: 106604. PMID: 34922004, PMCID: PMC8742790, DOI: 10.1016/j.prostaglandins.2021.106604.Peer-Reviewed Original ResearchConceptsPro-inflammatory T cellsEpoxyeicosatrienoic acidsSoluble epoxide hydrolaseSystemic inflammationT cellsAdipose tissueSubcutaneous abdominal adipose tissueEnzyme soluble epoxide hydrolaseComplex immune environmentT cell profileAbdominal adipose tissuePrediabetic adultsImmune environmentObese individualsSEH inhibitionObese personsTumor necrosisObese animalsInflammationCrossover designCell profilesGSK2256294Epoxide hydrolaseCentral contributorTissue
2016
Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites
Gamboa JL, Devin JK, Ramirez CE, Yu C, Nian H, Lee RH, Brown NJ. Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites. Pharmacology Research & Perspectives 2016, 4: e00221. PMID: 27069632, PMCID: PMC4804312, DOI: 10.1002/prp2.221.Peer-Reviewed Original ResearchProstacyclin metaboliteThromboxane productionProstacyclin productionBasal excretionDoses of ASAImmediate-release aspirinStable prostacyclin metaboliteBasal urinary excretionInhibition of basalAspirin therapyIntravenous bradykininASA groupThromboxane metabolitesUrinary excretionEndothelial productionTreatment periodHealthy subjectsCrossover designThromboxane formationAspirinPlatelet aggregationExcretionProstacyclinThromboxaneFifth day